Drug · CHEMBL1237122
CARBOPROST
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CARBOPROST. Drugs and targets, record CHEMBL1237122. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1237122
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- (15s)-15-methyl-pgf2.alpha., 15-methyl-pgf2.alpha., 15-methylprostaglandin f2.alpha., U-32,921, U-32921
- ChEMBL
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PTGFR | Prostaglandin F2-alpha receptor | Prostanoid FP receptor agonist | AGONIST | https://conductscience.org/library/genes/5737 |
Source ChEMBL
Diseases2
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| postpartum hemorrhage | Unknown | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=EFO_0009579 |
| Uterine Inertia | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_1001863 |
Source Open Targets
Trials5
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03584854 | Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial | Phase 4 | 100 | 2025-10-16 | carboprost | Its name | ClinicalTrials.gov |
| NCT02861482 | Early Usage of Bakri Ballon in Managing Postpartum Hemorrhage | 472 | hemabate | Its name | ClinicalTrials.gov | ||
| NCT01869556 | Comparison of IV Ergonovine With IM Carboprost, With Oxytocin IV, During Cesarean Section for Failure to Progress | 105 | carboprost | Its name | ClinicalTrials.gov | ||
| NCT00989027 | Impact of Uterotonic Agents on Isolated Human Myometrium | 56 | carboprost | Its name | ClinicalTrials.gov | ||
| NCT06285409 | Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium | 32 | carboprost | Its name | ClinicalTrials.gov |
Comparisons in its trials6
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 15-methyl Prostaglandin F2α vs Methylergonovine Maleate: Number of Subjects Requiring Additional Intervention | 4 of 50 | 5 of 50 | 100 | NCT03584854 | Trial comparisons |
| 15-methyl Prostaglandin F2α vs Methylergonovine Maleate: Number of Subjects Requiring Transfusion | 2 of 50 | 3 of 50 | 100 | NCT03584854 | Trial comparisons |
| 15-methyl Prostaglandin F2α vs Methylergonovine Maleate: Number of Subjects Receiving Additional Uterotonic | 17 of 50 | 15 of 50 | 100 | NCT03584854 | Trial comparisons |
| 15-methyl Prostaglandin F2α vs Methylergonovine Maleate: Number of Subjects Experiencing Severe Maternal Morbidity | 0 of 50 | 0 of 50 | 100 | NCT03584854 | Trial comparisons |
| 15-methyl Prostaglandin F2α vs Methylergonovine Maleate: deaths from any cause | 0 of 50 | 0 of 50 | 100 | NCT03584854 | Trial comparisons |
| 15-methyl Prostaglandin F2α vs Methylergonovine Maleate: serious adverse events | 0 of 50 | 0 of 50 | 100 | NCT03584854 | Trial comparisons |
Papers from its trials3
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1237122
GET https://conductscience.org/api/drugs/v1/CHEMBL1237122/targets